NO320194B1 - Vitronektin reseptor antagonister, anvendelse og fremstilling derav samt farmasoytisk sammensetning - Google Patents

Vitronektin reseptor antagonister, anvendelse og fremstilling derav samt farmasoytisk sammensetning Download PDF

Info

Publication number
NO320194B1
NO320194B1 NO19991590A NO991590A NO320194B1 NO 320194 B1 NO320194 B1 NO 320194B1 NO 19991590 A NO19991590 A NO 19991590A NO 991590 A NO991590 A NO 991590A NO 320194 B1 NO320194 B1 NO 320194B1
Authority
NO
Norway
Prior art keywords
tetrahydro
oxo
benzazepine
propyloxy
acetic acid
Prior art date
Application number
NO19991590A
Other languages
English (en)
Norwegian (no)
Other versions
NO991590L (no
NO991590D0 (no
Inventor
James Francis Callahan
Richard Mccullock Keenan
Russell Donovan Cousins
Irene Nijole Uzinskas
Chet Kwon
William Henry Miller
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO991590D0 publication Critical patent/NO991590D0/no
Publication of NO991590L publication Critical patent/NO991590L/no
Publication of NO320194B1 publication Critical patent/NO320194B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO19991590A 1996-10-02 1999-03-31 Vitronektin reseptor antagonister, anvendelse og fremstilling derav samt farmasoytisk sammensetning NO320194B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2732096P 1996-10-02 1996-10-02
US4377697P 1997-04-11 1997-04-11
PCT/US1997/018001 WO1998014192A1 (en) 1996-10-02 1997-10-01 Vitronectin receptor antagonists

Publications (3)

Publication Number Publication Date
NO991590D0 NO991590D0 (no) 1999-03-31
NO991590L NO991590L (no) 1999-05-31
NO320194B1 true NO320194B1 (no) 2005-11-14

Family

ID=26702318

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19991590A NO320194B1 (no) 1996-10-02 1999-03-31 Vitronektin reseptor antagonister, anvendelse og fremstilling derav samt farmasoytisk sammensetning

Country Status (37)

Country Link
EP (1) EP0957917B1 (xx)
JP (2) JP4491072B2 (xx)
KR (1) KR100589578B1 (xx)
CN (1) CN1114403C (xx)
AP (1) AP1463A (xx)
AR (1) AR008878A1 (xx)
AT (1) ATE312089T1 (xx)
AU (1) AU733417B2 (xx)
BG (1) BG64581B1 (xx)
BR (1) BR9712248B1 (xx)
CA (1) CA2267224C (xx)
CO (1) CO4900046A1 (xx)
CY (1) CY2576B1 (xx)
CZ (1) CZ299076B6 (xx)
DE (1) DE69734833T2 (xx)
DK (1) DK0957917T3 (xx)
DZ (1) DZ2320A1 (xx)
EA (1) EA002419B1 (xx)
ES (1) ES2252775T3 (xx)
HK (1) HK1023730A1 (xx)
HU (1) HU229221B1 (xx)
ID (1) ID19623A (xx)
IL (1) IL129243A (xx)
MA (1) MA24361A1 (xx)
MY (1) MY137606A (xx)
NO (1) NO320194B1 (xx)
NZ (1) NZ334953A (xx)
PE (1) PE10499A1 (xx)
PL (1) PL190859B1 (xx)
RO (1) RO119881B1 (xx)
SA (1) SA98180936B1 (xx)
SK (1) SK285029B6 (xx)
TR (1) TR199900737T2 (xx)
TW (1) TW487702B (xx)
UA (1) UA60311C2 (xx)
UY (2) UY24735A1 (xx)
WO (1) WO1998014192A1 (xx)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
IL135188A0 (en) * 1997-09-24 2001-05-20 Smithkline Beecham Corp Vitronectin receptor antagonist
TR200000792T2 (tr) * 1997-09-24 2000-09-21 Smithkline Beecham Corporation Vitronektin reseptör antagonistleri.
US6372719B1 (en) 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
WO2000038730A2 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
WO2000046215A1 (en) * 1999-02-03 2000-08-10 Merck & Co., Inc. Benzazepine derivatives as alpha-v integrin receptor antagonists
DE60007960T2 (de) * 1999-04-30 2004-10-21 Univ Michigan Ann Arbor Therapeutische Anwendungen von pro-apoptotischen Benzodiazepinen
AU6523200A (en) * 1999-08-06 2001-03-05 Smithkline Beecham Corporation Vitronectin receptor antagonists useful for the treatment of strokes
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
DE10027514A1 (de) * 2000-06-06 2002-01-03 Basf Ag Liganden von Integrinrezeptoren
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2436130A1 (en) 2001-01-29 2002-08-08 3-Dimensional Pharmaceuticals, Inc. Substituted indoles and their use as integrin antagonists
OA12505A (en) * 2001-04-10 2006-05-29 Smithkline Beecham Corp Method of inhibiting adhesion formation.
SE0101386D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab New compounds
WO2002090325A2 (en) * 2001-05-03 2002-11-14 Merck & Co., Inc. Benzazepinone alpha v integrin receptor antagonists
WO2003059251A2 (en) 2001-10-22 2003-07-24 The Scripps Research Institute Antibody targeting compounds
GB0215867D0 (en) * 2002-07-09 2002-08-14 Glaxosmithkline Spa Novel method and compounds
US7368566B2 (en) * 2003-04-04 2008-05-06 Smithkline Beecham Corporation Process and intermediates for preparing benzazepines
CN1964740A (zh) * 2004-04-02 2007-05-16 加利福尼亚大学董事会 治疗和预防与αVβ5整联蛋白有关的疾病的方法和组合物
AU2012216372B2 (en) * 2004-04-02 2015-01-22 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
UA87854C2 (xx) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-бензил)-2-фенілбутанаміди як модулятори рецептора андрогену$n-(2-бензил)-2-фенилбутанамиды как модуляторы рецептора андрогена
WO2006069079A2 (en) * 2004-12-21 2006-06-29 Smithkline Beecham Corporation Methods and formulations
WO2007064752A2 (en) * 2005-11-29 2007-06-07 Smithkline Beecham Corporation Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema
ES2457822T3 (es) 2007-11-08 2014-04-29 The General Hospital Corporation Procedimientos y composiciones de tratamiento de enfermedades proteinúricas
AU2008321770B2 (en) * 2007-11-16 2012-09-06 Ube Industries, Ltd. Benzazepinone compound
US8076475B2 (en) * 2008-03-06 2011-12-13 Glaxosmithkline Llc Process
WO2010093706A2 (en) 2009-02-10 2010-08-19 The Scripps Research Institute Chemically programmed vaccination
EP2415474B1 (en) * 2009-03-30 2013-08-28 Ube Industries, Ltd. Pharmaceutical composition for treatment or prevention of ophthalmic diseases
JP5572996B2 (ja) * 2009-05-15 2014-08-20 宇部興産株式会社 ベンズアゼピノン化合物を有効成分として含有する医薬
BR112012001463A2 (pt) 2009-07-24 2016-03-15 Univ California métodos e composições para tratar e prevenir doença associada à integrina alfavbeta5
CA2915237C (en) 2009-11-17 2017-10-10 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
EP2325194A1 (en) * 2009-11-24 2011-05-25 Glycotope GmbH Process for the purification of glycoproteins
WO2015181676A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
AU2021262281A1 (en) * 2020-04-26 2022-11-24 Jiangsu Nhwa Pharmaceutical Co., Ltd. 1,5-dihydro-2,4-benzodiazepine-3-one derivative and application thereof
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1041921C (zh) * 1992-12-21 1999-02-03 史密丝克莱恩比彻姆公司 双环血纤维蛋白原拮抗剂
JPH10504808A (ja) * 1994-06-29 1998-05-12 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗物質
JPH10504807A (ja) * 1994-06-29 1998-05-12 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗剤
US6008214A (en) * 1994-08-22 1999-12-28 Smithkline Beecham Corporation Bicyclic compounds
WO1996026190A1 (en) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція

Also Published As

Publication number Publication date
PE10499A1 (es) 1999-03-27
AU4746297A (en) 1998-04-24
JP2010006838A (ja) 2010-01-14
AR008878A1 (es) 2000-02-23
KR100589578B1 (ko) 2006-06-15
JP4491072B2 (ja) 2010-06-30
AU733417B2 (en) 2001-05-17
CZ299076B6 (cs) 2008-04-16
SK285029B6 (sk) 2006-04-06
HU229221B1 (en) 2013-09-30
BG64581B1 (bg) 2005-08-31
MY137606A (en) 2009-02-27
ID19623A (id) 1998-07-23
IL129243A (en) 2004-07-25
EP0957917B1 (en) 2005-12-07
CA2267224C (en) 2007-03-13
MA24361A1 (fr) 1998-07-01
CA2267224A1 (en) 1998-04-09
HUP9903769A3 (en) 2000-07-28
AP9901493A0 (en) 1999-03-31
HK1023730A1 (en) 2000-09-22
TR199900737T2 (xx) 1999-07-21
DZ2320A1 (fr) 2002-12-28
BR9712248A (pt) 1999-08-24
EP0957917A4 (en) 2002-05-15
EA002419B1 (ru) 2002-04-25
BR9712248B1 (pt) 2010-06-29
DE69734833T2 (de) 2006-07-13
NZ334953A (en) 2000-01-28
KR20000048816A (ko) 2000-07-25
CO4900046A1 (es) 2000-03-27
CN1238689A (zh) 1999-12-15
UY24735A1 (es) 1998-03-30
BG103299A (en) 2000-01-31
UA60311C2 (uk) 2003-10-15
ES2252775T3 (es) 2006-05-16
EP0957917A1 (en) 1999-11-24
TW487702B (en) 2002-05-21
IL129243A0 (en) 2000-02-17
JP2001501936A (ja) 2001-02-13
DK0957917T3 (da) 2006-04-18
CZ113299A3 (cs) 2000-03-15
SA98180936B1 (ar) 2006-05-30
PL332674A1 (en) 1999-09-27
ATE312089T1 (de) 2005-12-15
WO1998014192A1 (en) 1998-04-09
CN1114403C (zh) 2003-07-16
SK42599A3 (en) 1999-12-10
EA199900356A1 (ru) 2000-02-28
NO991590L (no) 1999-05-31
CY2576B1 (en) 2008-07-02
HUP9903769A2 (hu) 2000-03-28
NO991590D0 (no) 1999-03-31
AP1463A (en) 2005-09-10
UY24935A1 (es) 2001-07-31
DE69734833D1 (de) 2006-01-12
PL190859B1 (pl) 2006-02-28
RO119881B1 (ro) 2005-05-30

Similar Documents

Publication Publication Date Title
NO320194B1 (no) Vitronektin reseptor antagonister, anvendelse og fremstilling derav samt farmasoytisk sammensetning
US6239138B1 (en) Vitronectin receptor antagonist
CA2303846A1 (en) Vitronectin receptor antagonist
SK13292000A3 (sk) Antagonisty vitronektínového receptora, spôsob ich výroby, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty
CA2304000A1 (en) Vitronectin receptor antagonist
US6825188B2 (en) Vitronectin receptor antagonists
US6458814B1 (en) Vitronectin receptor antagonists
US20020123487A1 (en) Vitronectin receptor antagonist
US20020128257A1 (en) Vitronectin receptor antagonist
MXPA00002896A (en) Vitronectin receptor antagonist
MXPA01001386A (en) Vitronectin receptor antagonists

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees